Education
About Us
Working with TipRanks
Follow Us
Pharvaris (PHVS)
NASDAQ:PHVS
Top Page
Pharvaris
(NASDAQ:PHVS)
45Neutral
Positive Factors
Competitive Advantage
Deucrictibant appears competitive versus sebetralstat, showing potentially higher efficacy in reducing attack symptoms and faster relief times.
Efficacy and Safety
Pharvaris' oral deucrictibant has promising efficacy and safety in hereditary angioedema (HAE), both as an on-demand therapy for acute attacks and in long-term prophylactic settings.
Market Position
Deucrictibant is poised for broad adoption as it is the only biotech company with an oral candidate for both HAE prophylaxis and on-demand treatment.
Negative Factors
Market Challenges
Despite a handful of prophylactic and on-demand treatments for HAE, there is a significant need for more convenient (and efficacious) options, such as deucrictibant.
Market Competition
Despite the entrenched competition in HAE, there is a significant need for more convenient options, such as deucrictibant.
Trial Progress
The trial is progressing as planned with a target enrollment of ~120 patients and PHVS expects topline data in 1Q26, indicating a long wait for results.
Pharvaris (PHVS) vs. S&P 500 (SPY)
Market Cap
$861.96M
Dividend YieldN/A
Average Volume (3M)43.61K
Price to Earnings (P/E)―
Beta (1Y)1.21
Revenue GrowthN/A
EPS Growth16.70%
CountryUS
Employees82
SectorHealthcare
Sector Strength74
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.68
Shares Outstanding54,007,710
10 Day Avg. Volume42,300
30 Day Avg. Volume43,612
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$34.33Price Target Upside122.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
Pharvaris Business Overview & Revenue Model
Company DescriptionPharvaris (PHVS) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for rare diseases, specifically targeting hereditary angioedema (HAE) and other bradykinin-mediated diseases. The company's lead product candidate, PHVS416, is an oral small molecule designed to prevent and treat HAE attacks, providing an alternative to injectable therapies.
How the Company Makes MoneyPharvaris makes money primarily through the development and commercialization of its proprietary drug candidates targeted at rare diseases. The company's revenue model is centered around the successful progression of its drugs through clinical trials, resulting in regulatory approval and eventual commercialization. Revenue streams are expected to include sales of approved drugs, potential licensing agreements, and collaborations with larger pharmaceutical companies. As a clinical-stage company, Pharvaris may not yet have significant revenue and relies on funding from investors, partnerships, and grants to support its research and development activities.
Pharvaris Financial Statement Overview
Summary
Pharvaris is in the pre-revenue stage typical of biotech firms, exhibiting significant operating losses and negative cash flow due to high R&D expenses. The balance sheet shows strong equity and minimal debt, but the absence of revenue remains a significant risk.Income Statement
Pharvaris has consistently reported no revenue across all periods, which is typical for many biotechnology companies in the pre-revenue stage. The company shows a growing net loss, with significant negative EBIT and EBITDA margins, indicating high operational and financial challenges. However, this could reflect ongoing R&D investment necessary for future product development.25
Negative
Balance Sheet
Pharvaris maintains a strong equity position, with an equity ratio consistently above 90%, reflecting limited reliance on debt and substantial shareholder equity. However, the total debt is minimal, indicating prudent financial management, but the continual increase in liabilities could pose future risks if not managed alongside revenue growth.55
Neutral
Cash Flow
The company's operating cash flow is consistently negative, highlighting the ongoing cash burn typical for biotech firms in the R&D phase. While there have been significant financing inflows, likely from equity financing, the lack of positive free cash flow remains a concern for long-term sustainability without revenue generation.40
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| -200.10K | -252.27K | -150.19K | -80.46K | 0.00 | ― | EBIT |
| -127.08M | -96.91M | -86.74M | -65.90M | -25.01M | -7.99M | EBITDA |
| -127.58M | -96.85M | -86.58M | -54.06M | -25.01M | -8.01M | Net Income Common Stockholders |
| -131.37M | -100.88M | -76.33M | -42.73M | -25.99M | -8.04M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 1.35M | 391.23M | 161.84M | 209.35M | 98.63M | 20.33M | Total Assets |
| 1.36M | 398.69M | 167.73M | 212.09M | 101.10M | 20.60M | Total Debt |
| 0.00 | 238.91K | 436.82K | 250.18K | 0.00 | 0.00 | Net Debt |
| -1.35M | -390.99M | -161.40M | -209.10M | -98.63M | -20.33M | Total Liabilities |
| 120.33K | 14.65M | 18.47M | 7.14M | 5.31M | 1.92M | Stockholders Equity |
| 1.24M | 384.05M | 149.26M | 204.95M | 95.79M | 18.67M |
| Cash Flow | Free Cash Flow | ||||
| -108.00M | -93.14M | -67.29M | -44.73M | -21.54M | -6.69M | Operating Cash Flow |
| -107.60M | -93.05M | -67.16M | -44.60M | -21.50M | -6.68M | Investing Cash Flow |
| -404.13K | -89.98K | -124.30K | -130.03K | -42.98K | -13.48K | Financing Cash Flow |
| 256.41M | 325.39M | 8.65M | 143.67M | 101.20M | 21.63M |
Pharvaris Technical Analysis
Negative
15.46
Price Trends
16.89
Negative
18.78
Negative
18.63
Negative
Market Momentum
-0.30
Negative
41.34
Neutral
32.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PHVS, the sentiment is Negative. The current price of 15.46 is below the 20-day moving average (MA) of 15.72, below the 50-day MA of 16.89, and below the 200-day MA of 18.63, indicating a bearish trend. The MACD of -0.30 indicates Negative momentum. The RSI at 41.34 is Neutral, neither overbought nor oversold. The STOCH value of 32.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PHVS.
Pharvaris Risk Analysis
Pharvaris disclosed 82 risk factors in its most recent earnings report. Pharvaris reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Pharvaris Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $1.73B | ― | -9.85% | ― | 56.60% | -403.56% | |
60 Neutral | $3.47B | ― | -39.22% | ― | ― | -31.37% | |
56 Neutral | $1.88B | ― | -113.76% | ― | 229.74% | 70.23% | |
50 Neutral | $494.96M | ― | -182.71% | ― | 432.03% | 14.41% | |
49 Neutral | $6.95B | 0.65 | -53.57% | 2.47% | 21.51% | 0.74% | |
45 Neutral | $861.96M | ― | -58.16% | ― | ― | 16.70% |
* Healthcare Sector Average
Performance Comparison
PHVS
Pharvaris
15.40
-8.95
-36.76%
ANAB
AnaptysBio
17.08
-4.59
-21.18%
KNSA
Kiniksa Pharmaceuticals
23.36
3.39
16.98%
AKRO
Akero Therapeutics
45.22
20.09
79.94%
ARQT
Arcutis Biotherapeutics
17.01
7.40
77.00%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.